Protalix BioTherapeutics (NYSE:PLX) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a hold rating to a buy rating in a report released on Monday morning.

Protalix BioTherapeutics Stock Performance

PLX opened at $1.69 on Monday. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $1.90. The company’s 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.11. The stock has a market capitalization of $124.44 million, a PE ratio of -13.00 and a beta of 0.67.

Institutional Trading of Protalix BioTherapeutics

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Protalix BioTherapeutics in the first quarter valued at $198,000. Squarepoint Ops LLC raised its holdings in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after purchasing an additional 119,949 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter valued at about $80,000. Ground Swell Capital LLC purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth about $73,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth about $67,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.